Prostate Cancer

Prostate Cancer Diagnosis Ups Risk of Non-Cancer Hospitalizations

Prostate Cancer Diagnosis Ups Risk of Non-Cancer Hospitalizations

By

Risk of being admitted for non-cancer conditions is 38% higher in the year after a PCa diagnosis compared with a year before.

Adjuvant Therapies: Time to Fold or Double Down?

Adjuvant Therapies: Time to Fold or Double Down?

Benjamin T Ristau, MD, and Robert G. Uzzo, MD, FACS, examine why adjuvant therapies have been so ineffective.

Steps for Reducing CVD Risks in Prostate Cancer Patients

Steps for Reducing CVD Risks in Prostate Cancer Patients

By

The advice is useful as clinicians wait for formal guidelines.

Study Supports Hemiablation HIFU for Prostate Cancer

Study Supports Hemiablation HIFU for Prostate Cancer

By

Ablating only the prostate lobe with the tumor resulted in satisfactory mid-term functional outcomes, researchers reported.

Impact of USPSTF Rec Against PSA Screening Varied for Urologists, PCPs

Impact of USPSTF Rec Against PSA Screening Varied for Urologists, PCPs

Differential effect of 2012 USPSTF recommendations for primary care providers, urologists.

PCa Expectant Management Linked With Veterans' Age, Tumor Risk

PCa Expectant Management Linked With Veterans' Age, Tumor Risk

Patient age and tumor risk may be more strongly associated with use of expectant management for veterans with low-risk prostate cancer.

Simpler Prostate Cancer Grading System Proposed

Simpler Prostate Cancer Grading System Proposed

By

Tumors fall into 1 of 5 grade groups based on what pathologic findings indicate about prognosis.

Targeted Prophylaxis Before Prostate Biopsy Cuts Sepsis Risk

Targeted Prophylaxis Before Prostate Biopsy Cuts Sepsis Risk

By

Antibiotics selected based on results of pre-biopsy rectal swab cultures.

Chemoimmunotherapy May Be Effective for mCRPC

Chemoimmunotherapy May Be Effective for mCRPC

Combination angiogenesis inhibition can be safely administered with supportive measures in metastatic castration-resistant prostate cancer (mCRPC).

Modest Survival Benefit with EBRT + Brachytherapy in Intermediate PCa

Modest Survival Benefit with EBRT + Brachytherapy in Intermediate PCa

By

Combined radiotherapy remains controversial due to the increased potential for toxicities.

Fatal Prostate Cancer Linked to Balding

Fatal Prostate Cancer Linked to Balding

By

Any baldness is associated with a 56% higher risk of dying from the malignancy.

Many Seniors Have Non-Recommended PSA Screening

Many Seniors Have Non-Recommended PSA Screening

Rate of unnecessary screening was 15.7% in men 65 years and older.

PCa Surgery Patients Largely Unaware of Sexual Complications

PCa Surgery Patients Largely Unaware of Sexual Complications

By

Many men are unaware of erectile function recovery time and problems with ejaculation.

Superficial Sling Implantation Eases Post-RP Incontinence

Superficial Sling Implantation Eases Post-RP Incontinence

By

Modified technique improved stress urinary incontinence in nearly three-quarters of patients.

Lower PSA Thresholds Predict Increased PCa Risk in Veterans

Lower PSA Thresholds Predict Increased PCa Risk in Veterans

By

Prostate cancer is 1.4 times more likely to develop in those with a PSA level of 2.5 ng/mL or higher.

Enzalutamide More Effective than Bicalutamide in mCRPC Patients

Enzalutamide More Effective than Bicalutamide in mCRPC Patients

By

Enzalutamide reduced the risk of disease progression by 56% in mCRPC patients.

DNA Damage, Repair Profiling a Biomarker of PCa Progression

DNA Damage, Repair Profiling a Biomarker of PCa Progression

A newly developed profiling method may be helpful in the management of patients with high-risk prostate cancer.

Researchers Calculate Inherited Cancer Risk from Genes

Researchers Calculate Inherited Cancer Risk from Genes

Estimated 33% of overall risk is genetic; certain types of cancer have additional risk.

Zoledronic Acid Plus Celecoxib Aids Survival in Metastatic PCa

Zoledronic Acid Plus Celecoxib Aids Survival in Metastatic PCa

The addition of zoledronic acid and celecoxib increases survival for men with hormone therapy-naïve metastatic prostate cancer.

Black Men Produce Less PSA

Black Men Produce Less PSA

Equal serum prostate-specific antigen and prostate-specific antigen mass despite larger prostates.

Healthy Lifestyle After PCa Diagnosis Beneficial

Healthy Lifestyle After PCa Diagnosis Beneficial

By

Through diet and exercise, prostate cancer patients can decrease their risk of dying from their illness.

Adjuvant Bicalutamide With Salvage RT Improves Local PCa Survival

Adjuvant Bicalutamide With Salvage RT Improves Local PCa Survival

Anti-androgen therapy during and after salvage radiotherapy in patients with localized prostate cancer significantly improved long-term overall survival.

CTC Heterogeneity Predicts Hormone Therapy Response in mCRPC

CTC Heterogeneity Predicts Hormone Therapy Response in mCRPC

Patients with higher heterogeneity score did not respond well to hormone therapy.

Study: 5-ARIs Lower Prostate Cancer Progression Risk

Study: 5-ARIs Lower Prostate Cancer Progression Risk

By

Non-users of 5-alpha-reductase inhibitors had a nearly 2.6 times increased risk of pathologic progression than those who took the drugs.

Radium-223 Repeat Treatment Safe, Effective

Radium-223 Repeat Treatment Safe, Effective

By

Second round of 6 injections was well tolerated and continued to control disease progression in bone.

Early PSA Response to Abiraterone Predicts Better Outcomes

Early PSA Response to Abiraterone Predicts Better Outcomes

By

A 50% or greater PSA decline at 15 days after start of treatment was associated with increased progression-free and overall survival.

Statins May Prolong Abiraterone Treatment Duration

Statins May Prolong Abiraterone Treatment Duration

By

Researchers observed a trend toward longer time on drug among men with castration-resistant prostate cancer.

Aspirin May Reduce Risk of Lethal Prostate Cancer

Aspirin May Reduce Risk of Lethal Prostate Cancer

By

In large observational study, regular use—defined as 3 tablets per week—was associated with a 24% lower risk of dying from prostate cancer.

Bipolar Androgen Therapy Promising for Advanced Hormone-Sensitive PCa

Bipolar Androgen Therapy Promising for Advanced Hormone-Sensitive PCa

By

In a small study, high-dose testosterone given intermittently with androgen deprivation therapy lowered PSA levels without serious adverse effects.

Erectile Dysfunction Drugs Do Not Affect Prostate Cancer Relapse Risk

Erectile Dysfunction Drugs Do Not Affect Prostate Cancer Relapse Risk

By

No significant association found between phosphodiesterase type 5 inhibitor use and biochemical recurrence after radical treatment.

Sign Up for Free e-newsletters